Analytical Data
-
Gene name
C6
- Application
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P13671
-
Expression Region
Gln682~Ala934
-
Molecular Weight
32kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
C6 recombinant protein has emerged as a crucial focus in biomedical research, particularly in the fields of immunology and drug development. Originally derived from the immunoglobulin-like domain of the human protein C6, which plays a significant role in the complement system, the C6 recombinant protein has been engineered for various applications, including vaccine development and therapeutic interventions. The complement system is an essential component of the innate immune response, and its activation can lead to opsonization of pathogens, clearance of immune complexes, and initiation of inflammation. Disruptions or dysregulations in this system are associated with numerous diseases, including autoimmune disorders and infections. By studying C6 recombinant protein, researchers aim to understand its function in immune response modulation and its potential as a therapeutic agent. Furthermore, C6's ability to enhance antibody responses makes it an attractive candidate for use in adjuvants within vaccine formulations. This has significant implications for developing vaccines against infectious diseases and improving immune responses in vulnerable populations. Ongoing research is focused on optimizing the expression and purification processes of C6 recombinant protein, as well as exploring its interactions with other components of the immune system. As our understanding of the complement pathways and the role of C6 deepens, the potential for innovative therapeutic strategies continues to expand, underscoring the importance of this protein in contemporary medical research.
